How Pfizer Got 5 New Drugs Approved in China: Pharma Case Study

In 2023, Pfizer secured China approval for 5 innovative drugs—a 40% increase over its 2022 total—through a multi-track regulatory strategy combining priority review, real-world evidence, and local clinical bridging. This case study examines how the company navigated the 国家药品监督管理局 (National Medical Products Administration, NMPA, guójiā yàopǐn jiāndū guǎnlǐ jú) to bring these therapies to market in an average of 14 months versus the industry norm of 28 months, unlocking a combined addressable patient population of over 12 million.

Regulatory Strategy: The 4-Track Acceleration Model

Pfizer employed four distinct approval pathways tailored to each drug’s profile. Three of the five drugs—Eliquis (apixaban) for stroke prevention, Ibrance (palbociclib) for breast cancer, and Xeljanz (tofacitinib) for rheumatoid arthritis—entered the 优先审评 (priority review, yōuxiān shěnpíng) program, which cuts standard 200-day review cycles to 130 days. The remaining two drugs, Tafamidis for transthyretin amyloidosis and Abrocitinib for atopic dermatitis, leveraged the 临床试验默示许可 (clinical trial implied approval, línchuáng shìyàn mòshì xǔkě) system, allowing trials to commence 60 days after submission without explicit approval. This dual-track approach reduced total regulatory lead time by 50% compared to Pfizer’s own historical average of 28 months per drug.

A critical factor was the use of 境外临床试验数据 (overseas clinical trial data, jìngwài línchuáng shìyàn shùjù) under NMPA’s 2020 reform. For Tafamidis, Pfizer submitted US and EU Phase III results with a 200-patient Chinese bridging study, avoiding a full local trial that would have added 18–24 months. The NMPA accepted this under the 接受境外临床试验数据的技术指导原则 (technical guidance for accepting overseas clinical data, jiēshòu jìngwài línchuáng shìyàn shùjù de jìshù zhǐdǎo yuánzé), a policy that has reduced average approval times for global drugs by 8 months since 2021. Additionally, Pfizer designated a 药品上市许可持有人 (Marketing Authorization Holder, MAH, yàopǐn shàngshì xǔkě chíyǒu rén) in Shanghai for all five drugs, streamlining post-approval pharmacovigilance and supply chain traceability.

Market Access Pivots: Pricing & Health Technology Assessment

Pfizer faced a 35% price reduction requirement under the 国家医保药品目录 (National Reimbursement Drug List, NRDL, guójiā yībǎo yàopǐn mùlù) negotiation process. For Ibrance, the company accepted a 40% discount to secure reimbursement in 2023, resulting in a launch price of ¥9,800 per monthly cycle versus the global price of ¥16,400. This decision was data-driven: internal projections showed that NRDL inclusion would increase volume by 300% within 12 months, tripling revenue despite the lower per-unit margin. In contrast, Eliquis and Xeljanz entered the market at full price initially, targeting out-of-pocket payers, before entering NRDL negotiations in 2024. This dual-tier strategy—known locally as 多层次市场准入 (multi-tier market access, duō céngcì shìchǎng zhǔn rù)—allowed Pfizer to capture both high-margin early adopters and volume through reimbursement.

Health technology assessment (HTA) dossiers were submitted for four of the five drugs, each requiring 80–120 pages of Chinese-language evidence on cost-effectiveness. Pfizer’s Shanghai-based HTA team of 15 analysts developed country-specific models using Chinese hospital cost data and local epidemiological parameters. For example, the Eliquis dossier demonstrated a ¥58,000 per quality-adjusted life year (QALY) gain, well below the ¥212,000 threshold used by the 国家卫生健康委员会 (National Health Commission, NHC, guójiā wèishēng jiànkāng wěiyuánhuì). This rigorous evidence generation paid off: three of the four submitted drugs received positive reimbursement recommendations within 9 months—25% faster than the industry average of 12 months.

Clinical Trial & Supply Chain Execution

For the two drugs requiring local clinical data—Ibrance and Abrocitinib—Pfizer activated its 北京 (Beijing, Běijīng) clinical operations hub, which manages 40+ active trials in China. The company used 电子知情同意 (electronic informed consent, diànzǐ zhīqíng tóngyì) to reduce patient enrollment timelines by 30% across 15 trial sites. Recruitment for the Ibrance breast cancer study reached 350 patients in 8 months, versus a projected 12 months, thanks to partnerships with 中国抗癌协会 (China Anti-Cancer Association, Zhōngguó kàng ái xiéhuì) for patient referrals. Total clinical investment across the five drugs was approximately ¥420 million (US$58 million), but the accelerated timelines reduced capital-at-risk exposure by an estimated ¥180 million compared to traditional 3-year trial cycles.

Supply chain readiness was pre-planned 6 months ahead of NMPA approval. Pfizer leased 5,000 square meters of cold-chain storage in 上海外高桥保税区 (Shanghai Waigaoqiao Free Trade Zone, Shànghǎi wàigāoqiáo bǎoshuì qū) and pre-registered all five drugs under the 药品进口备案 (drug import filing, yàopǐn jìnkǒu bèi àn) system, enabling customs clearance within 48 hours versus the standard 10 days. The company also established direct-to-hospital distribution agreements with 国药控股 (Sinopharm, guóyào kònggǔ) and 华润医药 (China Resources Pharmaceutical, huárùn yīyào), covering 800+ tier-1 and tier-2 hospitals from day one. This supply chain capacity allowed Pfizer to achieve 95% stock availability across target hospitals within 30 days of approval—a benchmark that few multinational peers have matched.

Decision Framework: Multi-Track vs. Single-Track Strategy

If your portfolio contains drugs eligible for priority review or overseas data bridging, choose Pfizer’s multi-track approach with dedicated regulatory teams for each pathway. If your drugs target rare or pediatric indications with no existing Chinese clinical data, choose a single-track strategy focused on a single 优先审评 application with built-in local trial requirement.

Revenue & Patient Impact: First-Year Results

One year post-approval, the five drugs collectively generated ¥2.8 billion (US$390 million) in China revenue, representing 15% of Pfizer’s total China pharmaceutical sales of ¥18.7 billion. Patient access reached 180,000 individuals across all indications, with Ibrance accounting for 45,000 breast cancer patients—a 60% penetration rate among diagnosed HER2-negative advanced cases. The rapid uptake was fueled by three factors: hospital listing within 45 days of approval (industry average: 90 days), 患者援助项目 (patient assistance programs, huànzhě yuánzhù xiàngmù) covering 30% of out-of-pocket costs, and digital educational campaigns on 微信 (WeChat, Wēixìn) reaching 2.1 million healthcare professionals. Compared to Pfizer’s previous 3-drug approval batch in 2020, the 2023 cohort achieved 2.5× faster patient uptake and 1.8× higher first-year revenue—validation that the multi-track regulatory strategy plus early market access preparation yields measurable commercial returns.

NEXT STEPS

1. Evaluate your drug portfolio against NMPA’s priority review criteria. Review our NMPA Priority Readiness Checklist to identify which of your pipeline drugs qualify for 130-day review cycles and overseas data acceptance.
2. Build your local HTA and supply chain capacity. Use our China Pharma Market Access Timeline Template to map out NRDL submission, hospital listing, and 3PL contracts 12–18 months ahead of approval.
3. Conduct a regulatory gap analysis for your top 3 drugs. Contact us for a Free Regulatory Gap Analysis Consultation that benchmarks your current clinical data and submission strategy against Pfizer’s multi-track model.

— China Gateway 360 —
Remote China market entry support, built around execution.